What findings do clinical studies on TA-65® and telomere length provide? A systematic review and meta-analysis published on November 25, 2025, in the journal Cell Biology and Toxicology examined the scientific data regarding TA-65®.
The authors evaluated eight randomized controlled trials with a total of 750 participants. The focus was on white blood cell telomere length, physical function parameters, inflammatory markers, and safety data.
The publication reports statistically significant differences in leukocyte telomere length. However, a corresponding health benefit could not be demonstrated based on the functional metrics examined.
The following summarizes the key results, scientific limitations, and open questions.
What was examined in the meta-analysis?
The researchers led by Xiaojuan Su, Cheng Wang, Zhixian Gou, and Yi Qu systematically summarized the results of several clinical studies on TA-65®.
Eight randomized controlled trials with a total of 750 individuals were included. According to the authors, the average age was approximately 63 years.
The analysis specifically examined the following areas:
- Telomere length: Changes in telomere length in leukocytes, i.e., white blood cells.
- Physical functions: Metrics regarding physical performance and age-related functional impairments.
- Inflammatory markers: Changes in specific laboratory parameters, including CRP and interleukin-6.
- Safety: Reported adverse events and potential risks during the study periods.
For the statistical evaluation, the results of the included studies were pooled. The authors also examined potential differences between age groups and studies with different funding sources.
What are telomeres and why are they studied?
Telomeres are protective structures at the ends of our chromosomes. They consist of repeated DNA sequences and associated proteins.
Telomeres can shorten after many cell divisions. Other biological influences can also alter their length and functionality.
Telomere length is therefore studied in aging research as a potential biological marker.
A detailed explanation of these relationships can be found in our fundamental article What are telomeres and what is the function of telomerase?.
However, telomere length alone does not allow for a reliable determination of individual biological age.
What results did the meta-analysis show regarding telomere length?
The authors reported a statistically significant difference in leukocyte telomere length in favor of the groups treated with TA-65® compared to the control groups.
The pooled standardized effect size was SMD = 0.47 with a 95% confidence interval of 0.31 to 0.62.
A standardized effect size allows for the comparison of different study results. However, it does not describe a direct lengthening of telomeres by a specific number of base pairs.
The analysis also showed relevant statistical heterogeneity between the studies. This means the results were not entirely uniform.
Were there differences between age groups?
In the evaluated data, the authors reported a stronger statistical effect in participants over 60 years of age than in younger adults.
These differences stem from statistical subgroup analyses. They should not be interpreted as proof that older individuals derive a greater health benefit from TA-65®.
Did the changes lead to better physical performance?
An important part of the publication was the question of whether changes in telomere length were associated with measurable improvements in physical functions.
To this end, studies on physical performance and age-related functional impairments, among others, were evaluated.
The meta-analysis showed no statistically significant advantage for these functional endpoints.
This is essential for interpretation: a change in a biological metric does not automatically mean that health, performance, or life expectancy improves as a result.
What were the results for inflammatory markers?
Additionally, the authors examined certain inflammatory parameters, including C-reactive protein (CRP) and interleukin-6 (IL-6).
The pooled results showed no statistically significant improvement in these examined inflammatory markers.
Therefore, no confirmed anti-inflammatory effect of TA-65® in humans can be derived from the available data.
What do the safety data for TA-65® show?
The meta-analysis also evaluated adverse events from the included clinical investigations.
According to the authors, data from 487 participants were available for the safety evaluation.
Reported issues included mild gastrointestinal complaints, such as nausea and abdominal discomfort.
The authors did not identify any serious safety-related events during the observed study periods that were interpreted as a significant signal in their pooled analysis.
However, this result should not be equated with proof of complete safety.
What can be said about long-term cancer risks?
Telomerase plays a role not only in maintaining telomeres. Numerous cancer cells also utilize mechanisms to maintain their telomere length.
Therefore, the long-term safety of interventions in telomerase regulation is an important area of scientific research.
The meta-analysis did not identify a corresponding short-term oncological safety signal within the available observation periods.
However, the available data are not sufficient to safely exclude potential long-term cancer risks.
Larger and longer-term studies would be required for this.
What are the limitations of the meta-analysis?
Systematic reviews and meta-analyses can provide important insights because they pool results from multiple studies.
However, their validity depends significantly on the quality of the included studies.
For the present publication, the following aspects should be considered in particular:
- The included studies differed in terms of their research methods and results.
- Telomere length was determined using different laboratory techniques.
- Data for individual health endpoints were limited.
- Observation periods were insufficient for a conclusive assessment of long-term risks.
- A portion of the included studies was funded by companies.
The authors also reported that industry-funded studies showed larger effect estimates on average than independently funded research.
These differences should also be taken into account during scientific interpretation.
What does the meta-analysis mean for longevity research?
In longevity research, biological mechanisms related to aging processes and the maintenance of physical functions are investigated.
Telomeres are among the structures studied but are only one part of complex cellular processes.
The meta-analysis describes statistically measurable changes in a biological marker. A corresponding benefit regarding the examined functional aging parameters was not demonstrated.
Thus, the publication highlights the importance of distinguishing between changes in laboratory values and clinically relevant health outcomes.
Frequently asked questions about the TA-65® studies
How many people were examined in the meta-analysis?
According to the authors, eight randomized controlled trials with a total of 750 participants were summarized.
What changes in telomere length were found?
The pooled statistical analysis showed a significant difference in leukocyte telomere length in favor of the groups treated with TA-65®. However, the results differed between individual studies.
Does the meta-analysis prove that TA-65® slows down the aging process?
No. While the study reported changes in telomere length, it could not demonstrate a corresponding statistically significant advantage in the functional aging markers examined.
Is the long-term safety of TA-65® proven?
No. The available clinical data do not allow for a final assessment of potential long-term risks. Further independent long-term studies are required.
What is the difference between a single study and a meta-analysis?
A single study investigates a specific question within one research project. A meta-analysis pools the results of several suitable studies using statistical methods.
This can reveal overarching patterns. However, the results remain dependent on the quality and comparability of the included studies.
Conclusion: What do the current clinical studies show?
The systematic review and meta-analysis published in 2025 summarized eight randomized controlled trials with a total of 750 participants.
The authors reported a statistically significant difference in leukocyte telomere length in favor of TA-65®.
Conversely, no statistically significant advantages could be demonstrated for the examined functional aging markers and inflammatory parameters.
Long-term safety also remains an open scientific question.
The results complement research on telomere biology but do not provide evidence that TA-65® extends human lifespan, prevents diseases, or demonstrably slows the aging process.
Original scientific publication
Su, X., Wang, C., Gou, Z. & Qu, Y. (2025): Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis. Cell Biology and Toxicology, 41, Article 155.
Read the original scientific publication at Springer Nature →
